Navigation Links
Portola Pharmaceuticals Announces Positive Phase II EXPERT Results,and Additional Oral and Poster Presentations at the XXI Congress of,the International Society on Thrombosis and Haemostasis (ISTH)

SOUTH SAN FRANCISCO, July 02, 2007 /PRNewswire/ -- Portola Pharmaceuticals, Inc. announced today that it will present clinical and preclinical data on its oral Factor Xa inhibitor and on its intravenous and oral ADP receptor antagonist at the XXI Congress of the International Society of Thrombosis and Haemostasis (ISTH) in Geneva, Switzerland on July 6 through July 12, 2007.

The EXPERT poster, which outlines Phase II data on the Company's lead compound PRT054021, is entitled "Evaluation of the Factor Xa (FXA) Inhibitor, PRT054021 (PRT021), against Enoxaparin in Randomized Trial for the Prevention of Venous Thromboembolic Events after Total Knee Replacement (EXPERT)" and will be featured on July 10, 2007 at 5:30 p.m. CEST in the exhibition area.

    In addition, Portola will make the following presentations:


     "Initial Intravenous Experience with PRT060128 (PRT128), an Orally-

     Available, Direct-Acting, and Reversible P2Y12 Inhibitor," July 10 at

     5:30 p.m. (CEST) in the exhibition area.


     "PRT060128, A Novel, Direct-Acting Orally Available P2Y12 Antagonist,

     Confers Superior Antithrombotic Activity over Clopidogrel in a Mouse

     Thrombosis Model," July 11 at 10:00 a.m. (CEST) in Room Mont Blanc.


     "Differential Effects of Anti-Platelet Drugs on Thrombus Formation and

     Thrombus Stability," July 11, 2007 at 10:45 a.m. (CEST) in Room Mont

     Blanc.


     "Antagonism of Intrinsic Pathway Inhibits Tissue Factor (TF) -- Initiated

     Coagulation in a Platelet-Dependent Whole Blood Flow Assay" July 11 at

     5:30 p.m. (CEST) in the exhibition area.


     "Measurement of Thrombus Stability Predicts Coronary Events Post-

     Percutaneous Coronary Intervention (PCI)" will be presented on July 11 at

     5:30 p.m. (CEST) in the exhibition area.

About PRT054021 -- Portola's Factor Xa Inhibitor

PRT054021 is an oral Factor Xa inhibitor, an a nticoagulant initially being studied for the prevention of venous thromboembolism in patients who have undergone orthopedic surgery. Portola expects to develop PRT054021 for additional indications including stroke prevention in patients with atrial fibrillation and secondary prevention of myocardial infarction and stroke. Factor Xa is a validated target (one for which there are approved drugs on the market), and inhibiting its activity is believed to have superior anticoagulant properties compared to other targets such as thrombin. Portola believes its oral Factor Xa inhibitor will offer several advantages, including a long half-life to support once daily dosing and a low peak-to-trough concentration ratio, resulting in consistent activity that does not require monitoring or dose adjustment. In addition, PRT054021 is not excreted in the kidneys and therefore will not require dose adjustment in patients with impaired renal function.

About PRT060128 -- Portola's ADP Receptor Antagonist

PRT060128 is an antiplatelet drug that is the only intravenous (IV) and oral ADP receptor antagonist in clinical development. Portola believes that this compound may provide significant clinical benefit through immediate, high-level platelet inhibition in the acute setting and a seamless transition to predictable, reversible platelet inhibition in the chronic setting. Portola has studied this compound in a robust Phase I clinical development program including single ascending dose and multiple ascending dose studies with the oral formulation and a single ascending dose study with the IV formulation. Based on positive results from these studies, Portola intends to initiate its Phase II program in the second half of 2007.

About Portola Pharmaceuticals, Inc.

Portola Pharmaceuticals, Inc. is a privately-held biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapeutics for acute and chronic cardiovascular and vascul ar disease. Portola is currently developing two clinical stage antithrombotics. Portola's lead compound, PRT054021, is an oral Factor Xa inhibitor for the prevention of venous thromboembolism after orthopedic surgery, for stroke prevention in patients with atrial fibrillation and for secondary prevention of myocardial infarction (MI) and stroke. Portola's second compound, PRT060128, is an oral and intravenous ADP receptor antagonist for patients with acute coronary syndrome, for the prevention of cardiovascular events in patients undergoing percutaneous coronary intervention and for secondary prevention of MI and stroke.

CONTACT: Dan Budwick of BMC Communications, +1-212-477-9007, Ext. 14, forPortola Pharmaceuticals, Inc.

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Portola Pharmaceuticals Announces Positive Phase II Results for PRT054021 for Prevention of Venous Thromboembolism Following Total Knee Replacement Surgery
3. Portola Pharmaceuticals Presents Positive Phase I Data of Its ADP Receptor Antagonist at the American College of Cardiology
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
10. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
11. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... Dec. 6, 2016 A new study released ... (AIR 340B) projects the 340B Drug Pricing Program will continue ... time it is expected to exceed $23 billion in total ... 340B purchases surpass current Medicare Part B drug reimbursement purchases ... study – based on analysis of data on total drug ...
(Date:12/6/2016)... , Dec. 6, 2016 /PRNewswire/ - InMed ... progress today on its R&D program in the ... obstructive pulmonary disease (COPD). In June, 2015 InMed ... tool to identify the targets and potential active ... of COPD. Subsequently, with in vitro assays using ...
(Date:12/6/2016)... Tenn , Dec. 6, 2016  In response ... dependent on opioids every 25 minutes, a respected group ... company that will provide a holistic suite of services ... Based on his own experience trying to ... social entrepreneur Justin Lanning launched 180 ...
Breaking Medicine Technology:
(Date:12/7/2016)... , ... December 07, 2016 , ... Levels of a ... damage, according to a study appearing online in the journal Radiology. , Heart disease ... to increase significantly due to the rapidly aging population. Damage to both organs often ...
(Date:12/7/2016)... ... , ... They are musicians and librarians, fashion designers and fitness instructors, actors, ... England and around the nation. What do they have in common? All have been ... and compelling new photographic exhibit debuting Friday, December 9 at Logan International Airport in ...
(Date:12/7/2016)... Hollywood, Fl (PRWEB) , ... December 07, 2016 , ... When it came time to ... new heart. Just 40 minutes later, the Pediatric Heart Transplant team at Joe ... true making the Weston teen the hospital’s 30th heart transplant recipient. , “He was ...
(Date:12/7/2016)... ... December 07, 2016 , ... ODU, ... to the US market its advanced highly customizable contact technology solutions. , ODU ... These advanced technologies are ideal for a wide range of applications that require ...
(Date:12/7/2016)... Arbor, MI (PRWEB) , ... December 07, 2016 ... ... insurance and financial consultation services from offices located in South Lyon, Dewitt, Williamston, ... to benefit a basketball coach who needs treatment for a brain tumor. , ...
Breaking Medicine News(10 mins):